



Press release

Valby, 28 May 2014

## **Lundbeck to present new Brintellix® data at the Annual Society of Clinical Psychopharmacology (ASCP) Meeting**

**Data highlights safety and efficacy profile of Brintellix, including difficult to treat patients and special patient populations.**

H. Lundbeck A/S (Lundbeck) announced today that seven posters highlighting scientific data and clinical research will be presented at the upcoming Annual Society of Clinical Psychopharmacology (ASCP) held in Hollywood, Florida, from June 16-19, 2014. These data represent Lundbeck's ongoing commitment to clinical advances and are an important step in our pursuit of improving patients' functional outcome in Major Depressive Disorder (MDD).

The ASCP scientific committee has nominated, "The Effect of Vortioxetine on Sexual Dysfunction During the Treatment of Adults With Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD)," as a best poster and it will appear in the online 2014 ASCP Poster Session.

Brintellix® was discovered and developed in Lundbeck Research Laboratories. Brintellix® was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorders in adults and by the European Commission for the treatment of adults with Major Depressive Episodes, commonly referred to as depression. More recently, the Australian Therapeutic Goods Administration (TGA) approved Brintellix® for the treatment Major Depressive Disorders in April 2014.

### **Scientific Poster Presentations**

Below is a list of the titles and dates for the ASCP scientific presentations. All data is embargoed until the start of the meeting.

|  |  |  |
|--|--|--|
| <b>Poster number 40</b><br>Tuesday, 17 June<br>2014<br><br>Session Time:<br>11:15pm – 1:00pm | <b>Cognitive Domains Impacted by Vortioxetine<br/>Treatment of Patients with Major Depressive<br/>Disorder (MDD)</b> | Harrison JE,<br>Lophaven S, Olsen<br>CK. |
|--|--|--|

|   |   |   |
|---|---|---|
| <p><b>Poster number 41</b><br/>Tuesday, 17 June 2014</p> <p>Session Time:<br/>11:15am-1:00pm</p>  | <p><b>A Head-to-Head, Randomized, Comparison Study of Vortioxetine vs. Escitaopram in Patients Well Treated for MDD and Experiencing Treatment-emergent Sexual Dysfunction</b></p>        | <p>Jacobsen PL,<br/>Mahableshwarkar AR, Chen Y,<br/>Chrones L, Clayton AH.</p>              |
| <p><b>Poster number 49</b><br/>Tuesday, 17 June 2014</p> <p>Session Time:<br/>11:15am - 1:00pm</p>  | <p><b>Efficacy of Vortioxetine vs Placebo in Adults With Major Depressive Disorder (MDD): Meta-analyses of MADRS Single Items From 9 Short-term Studies</b></p>                           | <p>Thase ME,<br/>Mahableshwarkar AR, Loft H,<br/>Dragheim M.</p>                            |
| <p><b>Poster number 35</b><br/>Wednesday, 18 June 2014</p> <p>Session Time:<br/>12:00pm – 2:00pm</p>  | <p><b>The Effect of Vortioxetine on Sexual Dysfunction During the Treatment of Adults With Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD)</b></p>                  | <p>Jacobsen PL,<br/>Clayton AH,<br/>Mahableshwarkar AR, Palo W, Chen Y,<br/>Dragheim M.</p> |
| <p><b>Poster number 41</b><br/>Wednesday, 18 June 2014</p> <p>Session Time:<br/>12:00pm – 2:00pm</p>  | <p><b>Safety and Tolerability of Vortioxetine 15 and 20 mg in Subjects with Major Depressive Disorder (MDD): A Phase 3, Long-term, Open-label Extension Study</b></p>                     | <p>Jacobsen PL,<br/>Harper L, Serenko M, Chan S,<br/>Mahableshwarkar AR.</p>                |
| <p><b>Poster number 47</b><br/>Wednesday, 18 June 2014</p> <p>Session Time:<br/>12:00pm – 2:00pm</p>  | <p><b>In MDD Patients Switched After an Inadequate Response, the Efficacy and Tolerability of Vortioxetine versus Agomelatine is Independent of Previous Antidepressant Treatment</b></p> | <p>Papakostas G,<br/>Nielsen RZ,<br/>Dragheim M.</p>  |
| <p><b>ORAL PRESENTATION</b><br/>Wednesday, 18 June 2014</p> <p>Session Time:<br/>12:00pm - 2:00pm<br/>Westin Diplomat in Hollywood, Florida</p> | <p><b>The Efficacy of Vortioxetine in Patients with Major Depressive Disorder and High Levels of Anxiety Symptoms: A Meta-analysis</b></p>  | <p>Baldwin DS,<br/>Ménard F, Loft H,<br/>Chen Y,<br/>Mahableshwarkar, AR.</p>               |

## Contacts

Mads Kronborg, Media Relations Manager  
Telephone (direct): +45 36 43 28 51



### **About Lundbeck**

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our development and distribution of pioneering treatments continues to make a difference to people living with brain diseases. Our key areas of focus are alcohol dependence, Alzheimer's disease, depression/anxiety, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia and stroke.

Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales, and are committed to improving the quality of life of people living with brain diseases. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. We have research centers in China, Denmark and the United States, and production facilities in China, Denmark, France, Italy and Mexico. Lundbeck generated revenue of approximately DKK 15 billion in 2013 (EUR 2.0 billion; USD 2.7 billion).

For further information please visit [www.lundbeck.com](http://www.lundbeck.com).